VLX 600

Drug Profile

VLX 600

Alternative Names: VLX600

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karolinska Institute; Vivolux
  • Developer Vivolux
  • Class Cytostatics; Indoles; Methylhydrazines; Pyridines; Small molecules
  • Mechanism of Action Iron chelating agents; Mitochondrial protein inhibitors; UCHL5 protein inhibitors; USP14 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Refractory metastatic disease) in USA (IV, Infusion)
  • 03 May 2018 Vibolux terminates a phase I trial due to slow recruitment and lack of efficacy despite the completion of several dose steps in Solid tumours (Refractory metastatic disease) in USA (IV) (NCT02222363)
  • 17 May 2016 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top